Contribution to the clinical evaluation of beta-adrenergic blocking drugs: 1-p-nitrophenyl-2-isopropylaminoethanol (INPEA) as an antagonist of catecholamines in normal persons and in coronary disease patients.
D000293:Adolescent; D000328:Adult; D000605:Amino Alcohols / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000517:prevention & control; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001158:Arteries; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000037:antagonists & inhibitors*; D003327:Coronary Disease / Q000188:drug therapy*; D004562:Electrocardiography; D004837:Epinephrine / Q000494:pharmacology; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008722:Methods; D008875:Middle Aged; D009578:Nitrobenzenes / Q000627:therapeutic use*; D013565:Sympatholytics / Q000627:therapeutic use*
D000605:Amino Alcohols; D002395:Catecholamines; D009578:Nitrobenzenes; D013565:Sympatholytics; D007545:Isoproterenol; D004837:Epinephrine